Abstract

A blister packaging for a pharmaceutical cartridge or capsule and methods of forming same are disclosed.

IPC Classes  ?

• A61M 15/00 - Inhalators
• A61J 1/03 - Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
• B29C 51/14 - Shaping by thermoforming, e.g. shaping sheets in matched moulds or by deep-drawingApparatus therefor using multilayered preforms or sheets
• B29K 27/06 - PVC, i.e. polyvinylchloride
• B29K 27/12 - Use of polyvinylhalogenides as moulding material containing fluorine
• B29K 105/00 - Condition, form or state of moulded material
• B29L 9/00 - Layered products
• B29L 31/00 - Other particular articles
• B65B 9/04 - Enclosing successive articles, or quantities of material, between opposed webs one or both webs being formed with pockets for the reception of the articles, or of the quantities of material
• B65B 11/52 - Enclosing articles, or quantities of material, by disposing contents between two sheets, e.g. pocketed sheets, and securing their opposed free margins one sheet being rendered plastic, e.g. by heating, and forced by fluid pressure, e.g. vacuum, into engagement with the other sheet and contents, e.g. skin-packaging
• B65B 47/02 - Apparatus or devices for forming pockets or receptacles in or from sheets, blanks, or webs, comprising essentially a die into which the material is pressed or a folding die through which the material is moved with means for heating the material prior to forming
• B65B 51/10 - Applying or generating heat or pressure or combinations thereof
• B65D 6/00 - Containers having bodies formed by interconnecting or uniting two or more rigid, or substantially rigid, components made wholly or mainly of metal, plastics, wood or substitutes therefor
• B65D 75/32 - Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
• B65D 83/04 - Containers or packages with special means for dispensing contents for dispensing annular, disc-shaped, spherical or like small articles, e.g. tablets or pills

Abstract

Disclosed herein are pharmaceutical compositions and methods for the treatment and prophylaxis of bacterial infections of the skin, including, topical ulcers caused by Mycobacterium ulcerans in Buruli ulcers, and/or other topical infections and types of inflammation. In particular, the compositions comprise clofazimine, derivatives thereof, polymorphs thereof, and/or analogs thereof in a solution, suspension, creams, oils, emulsions, and ointments for topical application. Methods for making the compositions are also disclosed.

IPC Classes  ?

• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

A method for treating obesity associated with Prader Willi Syndrome is disclosed.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 38/28 - Insulins
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Goods & Services

Pharmaceutical preparations for the treatment of diabetes, endocrine diseases and disorders, metabolic diseases and disorders; pharmaceutical preparations for inhalation for the treatment of lung diseases and disorders, including, pulmonary arterial hypertension and interstitial lung diseases, including, idiopathic pulmonary fibrosis, and lung infections, including, mycobacterial infections. Medical devices, namely, devices for the administration of pharmaceuticals for inhalation for the treatment of lung diseases and disorders, including pulmonary arterial hypertension and interstitial lung diseases, including, idiopathic pulmonary fibrosis, and lung infections, including, mycobacterial infections; medical devices, namely, devices for the administration of pharmaceuticals for the treatment of diabetes, endocrine diseases and disorders, metabolic diseases and disorders.

Goods & Services

Pharmaceutical preparations for the treatment of diabetes, endocrine diseases and disorders, metabolic diseases and disorders; pharmaceutical preparations for inhalation for the treatment of lung diseases and disorders, including, pulmonary arterial hypertension and interstitial lung diseases, including, idiopathic pulmonary fibrosis, and lung infections, including, mycobacterial infections. Medical devices, namely, devices for the administration of pharmaceuticals for inhalation for the treatment of lung diseases and disorders, including pulmonary arterial hypertension and interstitial lung diseases, including, idiopathic pulmonary fibrosis, and lung infections, including, mycobacterial infections; medical devices, namely, devices for the administration of pharmaceuticals for the treatment of diabetes, endocrine diseases and disorders, metabolic diseases and disorders.

Goods & Services

Pharmaceutical preparations for inhalation for the treatment of lung infections, including, mycobacterial infections. Medical devices, namely, devices for the administration of pharmaceuticals for inhalation for the treatment of lung infections, including, mycobacterial infections.

Abstract

An ultra-rapid acting insulin composition and method for treating hyperglycemia in patients with diabetes are disclose. The composition is an inhalable dry powder composition comprising fumaryl diketopiperazine and insulin for pulmonary delivery, which significantly reduces the rates of hypoglycemic events in patients in patients on mealtime insulin therapy.

IPC Classes  ?

• A61K 38/28 - Insulins
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

A method for the synthesis of N-protected 3,6-aminoalkyl-2,5-diketopiperazines is provided. The method includes obtaining a cyclic α-N protected active amino ester and adding it to a mixture of an amine catalyst in an organic solvent.

IPC Classes  ?

• C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
• C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• C07D 241/10 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members

Abstract

An adapter (650) for transferring fluid between a first device (100) and a second device (800). The adapter comprises a first end (652) for receiving the first device, wherein the first end includes a side wall for locating around the first device (100). The adapter (650) further comprises a second end (654) for engaging the first device (100), and including a retaining member (656;658;662), wherein the retaining member (656;658;662) is operable to prevent removal of the first device (100) from the adapter (650) upon engagement of the first device (100) with the second end (654). The first end (652) and the second end (654) are open on both ends to comprise a through-bore extending through the adapter (650). In some cases, the first device (100) may be a drug pen containing insulin.

IPC Classes  ?

• A61J 1/20 - Arrangements for transferring fluids, e.g. from vial to syringe
• A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor

Goods & Services

(1) Pharmaceutical preparations for the treatment of diabetes, endocrine diseases and disorders, metabolic diseases and disorders; pharmaceutical preparations for inhalation for the treatment of lung diseases and disorders, including, pulmonary arterial hypertension and interstitial lung diseases, including, idiopathic pulmonary fibrosis, and lung infections, including, mycobacterial infections. (2) Medical devices, namely, devices for the administration of pharmaceuticals for inhalation for the treatment of lung diseases and disorders, including pulmonary arterial hypertension and interstitial lung diseases, including, idiopathic pulmonary fibrosis, and lung infections, including, mycobacterial infections; medical devices, namely, devices for the administration of pharmaceuticals for the treatment of diabetes, endocrine diseases and disorders, metabolic diseases and disorders.

Goods & Services

(1) Pharmaceutical preparations for inhalation for the treatment of lung infections, including, mycobacterial infections. (2) Medical devices, namely, devices for the administration of pharmaceuticals for inhalation for the treatment of lung infections, including, mycobacterial infections.

Goods & Services

Medical information services, namely, providing a website in the medical, pharmaceutical and health fields featuring information related to health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and drug compatibility in relation to therapy and treatment of individuals, adherence to pharmaceutical treatment protocols, and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals; Medical care consulting services in the fields of diagnostics, patient treatment and treatment protocols; Prescription reminder service for reminding patients of pharmaceutical preparation, dosage, allergic sensitivity, and refills for medical treatment purposes; Medical services in the nature of providing medical advice in the field of pharmaceutical use, patient health and treatment services; Medical services in the nature of providing information on health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and drug compatibility relating to therapy and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals

Abstract

A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin, oxyntomodulin and glucagon-like peptide.

IPC Classes  ?

• A61M 15/00 - Inhalators
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/22 - Hormones
• A61K 38/26 - Glucagons
• A61K 38/28 - Insulins
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Abstract

A fluid delivery device comprises a drive unit including an actuator and one or more first features and a cartridge filled with a fluid prior to being inserted into the housing. The cartridge having a fluid reservoir sealed at one end by a movable piston and sealed at another end by a pierceable septum. The cartridge includes one or more second features that are configured to align and mate with the one or more first features allowing the cartridge to be inserted into the drive unit. The piston is moveabe by the actuator once the cartridge is inserted into the drive unit.

IPC Classes  ?

• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
• A61M 5/28 - Syringe ampoules or cartridges, i.e. ampoules or cartridges provided with a needle

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diabetes, endocrine diseases and disorders, metabolic diseases and disorders; pharmaceutical preparations containing insulin for the treatment of diabetes, endocrine diseases and disorders, metabolic diseases and disorders; inhaler systems, comprised of inhalers and cartridges, both filled with pharmaceutical preparations for the treatment of diabetes, endocrine diseases and disorders, metabolic diseases and disorders

Abstract

A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 38/26 - Glucagons

Abstract

Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.

IPC Classes  ?

• A61K 38/28 - Insulins
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Goods & Services

Medical apparatus, namely, infusion and injection devices for administering drugs. Medical services; medical services in the field of diabetes; medical services in the nature of patient support relating to the treatment of diabetes; medical information services, namely, providing information relating to the treatment of diabetes.

Abstract

Inhalable compositions for treating pulmonary hypertension comprising treprostinil, derivative thereof or analogs thereof and a method for treating pulmonary arterial hypertension and/or idiopathic pulmonary fibrosis are disclosed herein. Methods of manufacturing pharmaceutical compositions are also disclosed. Compositions are based on diketopiperazine powders for pulmonary inhalation.

IPC Classes  ?

• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/191 - Acyclic acids having two or more hydroxy groups, e.g. gluconic acid
• A61P 9/12 - Antihypertensives

Abstract

Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.

IPC Classes  ?

• A61K 38/28 - Insulins
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)

Abstract

A fluid delivery device comprises a housing having a fluid reservoir. A needle is in fluid communication with the fluid reservoir in an engaged position and out of fluid communication with the fluid reservoir in armed and storage positions. A proximal end of a biasing member is coupled to the housing and a distal end of the biasing member is configured to deliver a force to the fluid reservoir. A piston member extends through the biasing member and is coupled to the distal end of the biasing member. The piston member is fixed with respect to the housing in a locked position such that the biasing member does not deliver the force to the fluid reservoir and moveable with respect to the housing in a released position such that the biasing member delivers the force to the fluid reservoir. Transitioning the needle from the storage position to the armed position transitions the piston from the locked position to the released position.

IPC Classes  ?

• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
• A61M 5/162 - Needle sets, i.e. connections by puncture between reservoir and tube
• A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters

Goods & Services

(1) Scientific and medical research and development in the fields of pharmaceuticals; Scientific and medical research and development in the fields of medical devices and medical technology used in connection with the delivery of pharmaceuticals via inhalation; Product design and development for others in the field of drug delivery systems, medical devices, and medical technology used in connection with the delivery of pharmaceuticals via inhalation. (2) Licensing to others of technology, namely, licensing of technologies related to drug formulations and medical devices used in connection with the delivery of pharmaceuticals via inhalation; Licensing to others intellectual property related to drug formulations and medical devices used in connection with the delivery of pharmaceuticals via inhalation.

Goods & Services

Scientific and medical research and development in the fields of pharmaceuticals; Scientific and medical research and development in the fields of medical devices and medical technology used in connection with the delivery of pharmaceuticals via inhalation; Product design and development for others in the field of drug delivery systems, medical devices, and medical technology used in connection with the delivery of pharmaceuticals via inhalation. Licensing to others of technology, namely, licensing of technologies related to drug formulations and medical devices used in connection with the delivery of pharmaceuticals via inhalation; Licensing to others intellectual property related to drug formulations and medical devices used in connection with the delivery of pharmaceuticals via inhalation.

Abstract

Cryogranulation systems with improved dispenser assemblies are provided for use in manufacturing frozen pellets of pharmaceutical substances in a fluid medium. Methods of cryogranulating the pharmaceutical substance in the fluid medium are also provided. In particular embodiments, the dispenser assembly is used with suspensions or slurries of pharmaceutical compositions including biodegradable substances, such as proteins, peptides, and nucleic acids. In certain embodiments, the pharmaceutical substance can be adsorbed to any pharmaceutically acceptable carrier particles suitable for making pharmaceutical powders. In one embodiment, the pharmaceutical carrier can be, for example, diketopiperazine-based microparticles. The dispenser assembly improves the physical characteristics of the cryopellets formed and minimizes product loss during processing.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61J 3/00 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
• A61K 38/28 - Insulins
• B01J 2/06 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a liquid medium

Goods & Services

Pharmaceutical preparations for inhalation for the treatment of lung infections, including, mycobacterial infections Medical devices, namely, devices for the administration of pharmaceuticals for inhalation for the treatment of lung infections, including, mycobacterial infections

Goods & Services

Pharmaceutical preparations for the treatment of diabetes, endocrine diseases and disorders, metabolic diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of lung diseases and disorders, including, pulmonary arterial hypertension and interstitial lung diseases, including, idiopathic pulmonary fibrosis, and lung infections, including, mycobacterial infections Medical devices, namely, devices for the administration of pharmaceuticals for inhalation for the treatment of lung diseases and disorders, including pulmonary arterial hypertension and interstitial lung diseases, including, idiopathic pulmonary fibrosis, and lung infections, including, mycobacterial infections; Medical devices, namely, devices for the administration of pharmaceuticals for the treatment of diabetes, endocrine diseases and disorders, metabolic diseases and disorders

Abstract

Provided are novel treprostinil based compounds, methods of treatment using the same, and their methods of making.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

A method, composition and kit for the treatment of fibrotic lung disease are disclosed. The method utilizes a combination product for inhalation comprising a therapeutic amount of a dry powder formulation provided in an inhaler to be administered to a subject in need by oral inhalation. The composition comprise diketopiperazine particles for pulmonary inhalation.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin

Abstract

The present invention relates to pharmaceutical compositions for inhalation comprising a therapeutically effective dose of clofazimine wherein the clofazimine is provided in the form of a suspension, and processes for their preparation. Furthermore, the present invention provides pharmaceutical combinations comprising clofazimine in the form of an aerosol for pulmonary inhalation. The combinations and compositions provided by the present invention may be used in the treatment and/or prophylaxis of pulmonary infections caused by mycobacteria and other gram-positive bacteria, and of pulmonary fungal infections.

IPC Classes  ?

• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 9/10 - DispersionsEmulsions
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 47/02 - Inorganic compounds
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

Described herein are interactive apparatus and methods for sensing and measuring real-time characteristic patterns of a subject's use of a dry powder inhalation system. The devices can be used in a wired or wireless communication mode to communicate with a display to assess the subject's usage of the inhalation system, to evaluate the performance of the inhalation system and/or to detect the characteristics profile of a dry powder formulation emitted from the inhalation system in use.

IPC Classes  ?

• A61M 15/00 - Inhalators
• A61B 5/087 - Measuring breath flow
• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine

Goods & Services

Medical information services, including providing medical, pharmaceutical and health information related to health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and/or drug compatibility in relation to therapy and treatment of individuals, adherence to pharmaceutical protocols, and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals via a website; medical care consulting services in the fields of diagnostics, patient treatment and treatment protocols.

Abstract

Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 38/28 - Insulins

Goods & Services

Providing a database featuring information about patient reimbursement and insurance coverage for pharmaceuticals and medical devices; insurance consultation services, namely, assisting physician offices and patients to identify the scope of coverage offered by patient medical and pharmaceutical insurance; insurance benefits verification services in the medical field; insurance consultation services, namely, assisting physician offices and patients to obtain prior authorization for medical and pharmaceutical insurance claims and the preparation and submission of related paperwork and assisting physician offices and patients to appeal denial of medical and pharmaceutical insurance claims and the preparation and submission of related paperwork Providing temporary use of online non-downloadable software that assists patients with the filling and delivery of pharmaceutical prescriptions through communication with patient pharmacies Medical information services, namely, providing a website in the medical, pharmaceutical and health fields featuring information related to health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and drug compatibility in relation to therapy and treatment of individuals, adherence to pharmaceutical protocols, and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical care consulting services in the fields of diagnostics, patient treatment and treatment protocols; prescription reminder service for reminding patients of pharmaceutical preparation, dosage, allergic sensitivity, and refills for medical treatment purposes; medical services in the nature of providing medical advice in the field of pharmaceutical use, patient health and treatment services; medical services in the nature of providing information on health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and drug compatibility relating to therapy and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals

Abstract

Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 38/13 - Cyclosporins
• A61K 38/25 - Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
• A61K 38/27 - Growth hormone [GH], i.e. somatotropin
• A61K 38/28 - Insulins
• A61K 38/29 - Parathyroid hormone, i.e. parathormoneParathyroid hormone-related peptides
• A61K 9/50 - Microcapsules
• A61K 38/22 - Hormones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/26 - Glucagons

Abstract

A method, composition and kit for the treatment of fibrotic lung disease are disclosed. The method utilizes a combination product for inhalation comprising a therapeutic amount of a dry powder formulation provided in an inhaler to be administered to a subject in need by oral inhalation. The composition comprises diketopiperazine particles and a kinase inhibitor for oral inhalation.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• C07D 213/04 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
• C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 241/02 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
• C07D 495/04 - Ortho-condensed systems

Goods & Services

Medical apparatus, namely, infusion and injection devices for administering drugs Medical services; Medical services in the field of diabetes; Medical services in the nature of patient support relating to the treatment of diabetes; Medical information services, namely, providing information relating to the treatment of diabetes

Abstract

A medicament delivery device may comprise a medicament chamber configured to hold a medicament, a plunger configured to move relative to the medicament chamber to expel the medicament from the medicament chamber, a pin configured to move from a first pin position wherein the pin prevents movement of the plunger to a second pin position wherein the pin allows movement of the plunger, an actuation assembly configured to move the pin from the first pin position to the second pin position, and a needle coupled to the medicament chamber. The medicament may flow through the needle from the medicament chamber to a user. The actuation assembly may be configured to automatically move the pin after a predetermined time delay.

IPC Classes  ?

• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
• A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles

Abstract

A medicament delivery assembly comprises a delivery device configured to deliver medicament to a user, a communication accessory releasably coupled to the delivery device, and one or more sensors configured to sense a condition of the delivery device. The communication accessory may be configured to receive a first signal from the one or more sensors assembly and to send a second signal to an external device.

IPC Classes  ?

• A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• A61M 5/31 - Syringes Details

Goods & Services

Scientific and medical research and development in the fields of pharmaceuticals; Scientific and medical research and development in the fields of medical devices and medical technology used in connection with the delivery of pharmaceuticals via inhalation; Product design and development for others in the field of drug delivery systems, medical devices, and medical technology used in connection with the delivery of pharmaceuticals via inhalation Licensing to others of technology, namely, licensing of technologies related to drug formulations and medical devices used in connection with the delivery of pharmaceuticals via inhalation; Licensing to others intellectual property related to drug formulations and medical devices used in connection with the delivery of pharmaceuticals via inhalation

Abstract

A method of treating a patient with diabetes is provided. The method includes determining a number of powdered insulin units required for each different meal in a day, rounding the number of powdered insulin units up to a nearest predetermined powdered insulin dose for each of the different meals, determining a number and capacity of powdered insulin cartridges to achieve the nearest predetermined powdered insulin doses for each of the different meals, multiplying the number of powdered insulin cartridges of each capacity for each different meal by a number of the different meals in a prescription period, determining a number of boxes of powdered insulin cartridges of each capacity for the prescription period, and prescribing the determined number of boxes of powdered insulin cartridges of each capacity.

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
• G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices

Abstract

A fluid delivery device comprises a fluid reservoir for containing medicament. The fluid reservoir is sealed proximate one end with a sliding seal piston. A delivery path is configured to fluidly couple the fluid reservoir and a patient wearing the fluid delivery device. A basal engine mechanism is configured to directly or indirectly move the sliding seal piston in the fluid reservoir at a controlled basal rate. A bolus mechanism configured to move the basal engine relative to the fluid reservoir and directly or indirectly move the sliding seal piston in the fluid reservoir a discrete bolus amount at a time.

IPC Classes  ?

• A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
• A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
• A61M 5/142 - Pressure infusion, e.g. using pumps

Abstract

Disclosed herein are methods of treatment and/or prophylaxis of viral infections. In particular, the method is for the administration by inhalation of a pharmaceutically effective dose of clofazimine, which is provided in the form of a solution, suspension, or as a dry powder, in formulations suitable for inhalation.

IPC Classes  ?

• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof

Abstract

A fluid delivery device includes a housing having a bottom surface configured to be coupled to the skin surface. The fluid delivery device includes a cartridge prefilled with a fluid and configured to be inserted into the housing. The cartridge has a septum configured to be generally perpendicular to the bottom surface when the cartridge is inserted in the housing. The fluid delivery device includes a needle assembly that has a needle that includes a fluid coupling end and a delivery end. The fluid coupling end of the needle is fluidly disengaged from the cartridge in an initial position. The delivery end of the needle extends past the plane of the bottom surface and the fluid coupling end of the needle extends through the septum in a deployed position.

IPC Classes  ?

• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
• A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
• A61M 5/158 - Needles
• A61M 5/162 - Needle sets, i.e. connections by puncture between reservoir and tube
• A61M 5/28 - Syringe ampoules or cartridges, i.e. ampoules or cartridges provided with a needle

Abstract

A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, with or without a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, hormones such as insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, diseases and disorders, including endocrine disease such as diabetes and/or obesity.

IPC Classes  ?

• A61M 15/00 - Inhalators
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
• A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes

Abstract

Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.

IPC Classes  ?

• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 9/14 - Particulate form, e.g. powders
• A61K 38/28 - Insulins
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61M 15/00 - Inhalators
• C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 38/19 - CytokinesLymphokinesInterferons

Abstract

Mycobacterium ulceransMycobacterium ulcerans in Buruli ulcers, and/or other topical infections and types of inflammation. In particular, the compositions comprise clofazimine, derivatives thereof, polymorphs thereof, and/or analogs thereof in a solution, suspension, creams, oils, emulsions, and ointments for topical application. Methods for making the compositions are also disclosed.

IPC Classes  ?

• A61K 31/33 - Heterocyclic compounds
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diabetes, endocrine diseases and disorders, metabolic diseases and disorders; pharmaceutical preparations containing insulin for the treatment and prevention of diabetes Medical devices, namely, inhalers for medical use, cartridges for medical use, and inhaler systems comprised of inhalers and cartridges for medical use for the inhalation of pharmaceuticals, all provided empty; Medical devices for use as a component of inhaler systems for medical use, namely, devices used to measure patient inhalation effort and to indicate dosing of medication, all provided empty and used for the inhalation of pharmaceuticals

Abstract

Dry powder inhaler systems for pulmonary delivery of pharmaceuticals are disclosed.

IPC Classes  ?

• A61M 15/00 - Inhalators

Abstract

Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.

IPC Classes  ?

• A61K 38/28 - Insulins
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Inhalable compositions for treating pulmonary hypertension comprising treprostinil, derivative thereof or analogs thereof and a method for treating pulmonary hypertension, pulmonary arterial hypertension and/or idiopathic pulmonary fibrosis are disclosed herein. Methods of manufacturing pharmaceutical compositions are also disclosed. Pharmaceutical compositions are based on crystalline diketopiperazine dry powders for pulmonary inhalation.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61M 15/00 - Inhalators
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

Inhalable compositions for treating pulmonary hypertension comprising treprostinil, derivative thereof or analogs thereof and a method for treating pulmonary hypertension, pulmonary arterial hypertension and/or idiopathic pulmonary fibrosis are disclosed herein. Methods of manufacturing pharmaceutical compositions are also disclosed. Pharmaceutical compositions are based on crystalline diketopiperazine dry powders for pulmonary inhalation.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61M 15/00 - Inhalators
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

Inhalable compositions for treating pulmonary hypertension comprising treprostinil, derivative thereof or analogs thereof and a method for treating pulmonary arterial hypertension and/or idiopathic pulmonary fibrosis are disclosed herein. Methods of manufacturing pharmaceutical compositions are also disclosed. Compositions are based on diketopiperazine powders for pulmonary inhalation.

IPC Classes  ?

• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/191 - Acyclic acids having two or more hydroxy groups, e.g. gluconic acid
• A61P 9/12 - Antihypertensives
• A61K 9/00 - Medicinal preparations characterised by special physical form

Goods & Services

(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diabetes, endocrine diseases and disorders; pharmaceutical preparations containing insulin; pharmaceutical preparations for the treatment of metabolic diseases and disorders, lung diseases and disorders, including, pulmonary arterial hypertension, interstitial lung diseases and pulmonary fibrosis (2) Medical devices, namely, inhalers, cartridges, and inhaler systems comprising inhalers and cartridges for administration of pharmaceuticals, all provided empty; medical devices, namely, instruments and apparatus provided empty used for the inhalation of pharmaceuticals (1) Medical information services, namely, providing a website in the medical, pharmaceutical and health fields featuring information related to health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and drug compatibility in relation to therapy and treatment of individuals, adherence to pharmaceutical protocols, and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical care consulting services in the fields of diagnostics, patient treatment and treatment protocols; prescription reminder service for reminding patients of pharmaceutical preparation, dosage, allergic sensitivity, and refills for medical treatment purposes; medical services in the nature of providing medical advice in the field of pharmaceutical use, patient health and treatment services; medical services in the nature of providing information on health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and drug compatibility relating to therapy and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals

Goods & Services

(1) Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diabetes, endocrine diseases and disorders; pharmaceutical preparations containing insulin; pharmaceutical preparations for the treatment of metabolic diseases and disorders, lung diseases and disorders, including, pulmonary arterial hypertension, interstitial lung diseases and pulmonary fibrosis (2) Medical devices, namely, inhalers, cartridges, and inhaler systems comprising inhalers and cartridges for administration of pharmaceuticals, all provided empty; medical devices, namely, instruments and apparatus provided empty used for the inhalation of pharmaceuticals (1) Medical information services, namely, providing a website in the medical, pharmaceutical and health fields featuring information related to health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and drug compatibility in relation to therapy and treatment of individuals, adherence to pharmaceutical protocols, and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical care consulting services in the fields of diagnostics, patient treatment and treatment protocols; prescription reminder service for reminding patients of pharmaceutical preparation, dosage, allergic sensitivity, and refills for medical treatment purposes; medical services in the nature of providing medical advice in the field of pharmaceutical use, patient health and treatment services; medical services in the nature of providing information on health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and drug compatibility relating to therapy and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals

Goods & Services

(1) Licensing to others of technology and intellectual property in connection with medical devices

Goods & Services

Licensing to others of technology and intellectual property in connection with medical devices.

Abstract

A dry powder inhaler including replaceable cartridges containing a dry powder for local or systemic delivery through the pulmonary tract and lungs is disclosed. The inhalers are used with inhalable dry powders, including medicament formulations comprising active agents for local or systemic delivery and for the treatment of diseases such as, pulmonary hypertension, cardiovascular disease, anaphylaxis, diabetes, obesity, cancer, and other diseases, or symptoms associated with these and other diseases, such as nausea, vomiting, pain and inflammation.

IPC Classes  ?

• A61M 15/00 - Inhalators
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion

Abstract

Disclosed embodiments relate to improved methods for the synthesis of activated fumarate intermediates and their use in chemical synthesis. Disclosed embodiments describe the synthesis of activated fumarate esters including those derived from activating groups including: 4-nitrophenyl, diphenylphophoryl azide, pivaloyl chloride, chlorosulfonyl isocyanate, p-nitrophenol, MEF, trifluoroacetyl and chlorine, for example, ethyl fumaroyl chloride and the subsequent use of the activated ester in situ. Further embodiments describe the improved synthesis of substituted aminoalkyl-diketopiperazines from unisolated and unpurified intermediates allowing for improved yields and reactor throughput.

IPC Classes  ?

• C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
• C07C 67/30 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
• C07C 67/39 - Preparation of carboxylic acid esters by oxidation of groups which are precursors for the acid moiety of the ester
• C07C 201/12 - Preparation of nitro compounds by reactions not involving the formation of nitro groups

Abstract

The disclosed embodiments detail improved methods for the synthesis of diketopiperazines from amino acids. In particular improved methods for the cyclocondensation and purification of N-protected 3,6-(aminoalkyl)-2,5-diketopiperazines from N-protected amino acids. Disclosed embodiments describe methods for the synthesis of 3,6-bis-[N-protected aminoalkyl]-2,5-diketopiperazine comprising heating a mixture of an amino acid in the presence of a catalyst in an organic solvent. The catalyst is selected from the group comprising sulfuric acid, phosphoric acid, p-toluenesulfonic acid, 1-propylphosphonic acid cyclic anhydride, tributyl phosphate, phenyl phosphonic acid and phosphorous pentoxide among others. The solvent is selected from the group comprising: dimethylacetamide, N-methyl-2-pyrrolidone, diglyme, ethyl glyme, proglyme, ethyldiglyme, m-cresol, p-cresol, o-cresol, xylenes, ethylene glycol and phenol among others.

IPC Classes  ?

• C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides

Abstract

Disclosed herein are diketopiperazine microparticles having high capacity for adsorbing a drug or active agent. In particular, the diketopiperazine microparticle are formed using fumaryl diketopiperazine and can comprise a drug in large doses for the treatment of disease or disorders by pulmonary delivery via oral inhalation.

IPC Classes  ?

• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/14 - Particulate form, e.g. powders
• A61K 38/28 - Insulins
• A61K 9/50 - Microcapsules

Abstract

Described herein are an interactive apparatus and methods for sensing and measuring real-time characteristic patterns of a subject's use of a dry powder inhalation system. The inhaler device can be used in a wireless communication mode to communicate with a display to assess the subject's usage of the inhalation system concurrently as the inhalation is performed and thus the subject's inhalation can be evaluated as well as the performance of the inhalation system. The system can also detect the identity of the medicament, its dosage, lot, expiration, etc. and the characteristics profile of a dry powder formulation emitted from the inhalation system in use.

IPC Classes  ?

• A61M 15/00 - Inhalators
• G09B 5/02 - Electrically-operated educational appliances with visual presentation of the material to be studied, e.g. using film strip
• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
• A61K 38/28 - Insulins
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Goods & Services

Licensing to others of technology, namely, licensing of technologies related to drug formulations and medical devices used in connection with the delivery of pharmaceuticals via inhalation; Licensing to others intellectual property related to drug formulations and medical devices used in connection with the delivery of pharmaceuticals via inhalation

Goods & Services

Scientific and medical research and development in the field of medical devices and apparatuses for drug delivery, namely, disposable pumps for subcutaneous infusion of pharmaceutical formulations; product design and development for others in the field of medical devices and medical technology for drug delivery

Goods & Services

Downloadable software in the nature of a mobile application for reading information and data from a medical device, for use by medical professionals and/or patients; downloadable software for coaching and teaching intended to assist users to properly use the inhaler, namely, training with inhalers without medication for medical instruction purposes to teach inhaler use technique.

Abstract

A method for preventing or reducing adverse effects such as profuse sweating, nausea and vomiting, which normally are associated with subcutaneous and intravenous administration of glucagon-like peptide 1 (GLP-1) therapy is provided. In particular, the method comprises the rapid administration of a GLP-1 formulation into the pulmonary circulation such as by inhalation, directly into pulmonary alveolar capillaries using a dry powder drug delivery system.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 38/26 - Glucagons
• A61K 38/28 - Insulins
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61M 15/00 - Inhalators

Abstract

The present invention relates to pharmaceutical compositions for inhalation comprising a therapeutically effective dose of clofazimine wherein the clofazimine is provided in the form of dry powder, and processes for their preparation. Furthermore, the present invention provides pharmaceutical combinations comprising clofazimine in the form of an aerosol for pulmonary inhalation. The combinations and compositions provided by the present invention may be used in the treatment and/or prophylaxis of pulmonary infections caused by mycobacteria and other gram-positive bacteria, and of pulmonary fungal infections.

IPC Classes  ?

• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/606 - Salicylic acidDerivatives thereof having amino groups
• A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems

Abstract

A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 38/26 - Glucagons

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diabetes, endocrine diseases and disorders; pharmaceutical preparations containing insulin; pharmaceutical preparations for the treatment of metabolic diseases and disorders, lung diseases and disorders, including, pulmonary arterial hypertension, interstitial lung diseases and pulmonary fibrosis Medical devices, namely, inhalers, cartridges, and inhaler systems comprising inhalers and cartridges for administration of pharmaceuticals, all provided empty; medical devices, namely, instruments and apparatus provided empty used for the inhalation of pharmaceuticals Medical information services, namely, providing a website in the medical, pharmaceutical and health fields featuring information related to health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and drug compatibility in relation to therapy and treatment of individuals, adherence to pharmaceutical protocols, and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical care consulting services in the fields of diagnostics, patient treatment and treatment protocols; prescription reminder service for reminding patients of pharmaceutical preparation, dosage, allergic sensitivity, and refills for medical treatment purposes; medical services in the nature of providing medical advice in the field of pharmaceutical use, patient health and treatment services; medical services in the nature of providing information on health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and drug compatibility relating to therapy and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals

Goods & Services

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of diabetes, endocrine diseases and disorders; pharmaceutical preparations containing insulin; pharmaceutical preparations for the treatment of metabolic diseases and disorders, lung diseases and disorders, including, pulmonary arterial hypertension, interstitial lung diseases and pulmonary fibrosis Medical devices, namely, inhalers, cartridges, and inhaler systems comprising inhalers and cartridges for administration of pharmaceuticals, all provided empty; medical devices, namely, instruments and apparatus provided empty used for the inhalation of pharmaceuticals Medical information services, namely, providing a website in the medical, pharmaceutical and health fields featuring information related to health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and drug compatibility in relation to therapy and treatment of individuals, adherence to pharmaceutical protocols, and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical care consulting services in the fields of diagnostics, patient treatment and treatment protocols; prescription reminder service for reminding patients of pharmaceutical preparation, dosage, allergic sensitivity, and refills for medical treatment purposes; medical services in the nature of providing medical advice in the field of pharmaceutical use, patient health and treatment services; medical services in the nature of providing information on health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and drug compatibility relating to therapy and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals

Goods & Services

(1) Downloadable software in the nature of a mobile application for reading information and data collected from inhalers, for use by medical professionals and patients; downloadable software for coaching and teaching intended to assist users to properly use the inhaler, namely, training with inhalers without medication for medical instruction purposes to teach inhaler use technique.

Goods & Services

Licensing to others of technology, namely, licensing of technologies related to medical devices; Licensing to others of intellectual property related to medical devices

Abstract

Embodiments of this invention relate to a fluid delivery device. The fluid delivery device comprises a fluid reservoir for containing a fluid, a first drive mechanism configured to remove a predetermined amount of the fluid from the fluid reservoir when the first drive mechanism is actuated, a needle, a septum and a housing having an orifice. Also disclosed is a method for dispensing a fluid from a fluid delivery device into a patient.

IPC Classes  ?

• A61M 5/155 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons pressurised by gas
• A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
• A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 5/158 - Needles

Goods & Services

Medical device for filling infusion pumps with fluids excluding vials, syringes, cartridges, and pharmaceutical primary containers

Abstract

An adapter (650) for transferring fluid between a first device (100) and a second device (800). The adapter comprises a first end (652) for receiving the first device, wherein the first end includes a side wall for locating around the first device (100). The adapter (650) further comprises a second end (654) for engaging the first device (100), and including a retaining member (656; 658; 662), wherein the retaining member (656; 658; 662) is operable to prevent removal of the first device (100) from the adapter (650) upon engagement of the first device (100) with the second end (654). The first end (652) and the second end (654) are open on both ends to comprise a through-bore extending through the adapter (650). In some cases, the first device (100) may be a drug pen containing insulin.

IPC Classes  ?

• A61J 1/20 - Arrangements for transferring fluids, e.g. from vial to syringe
• A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor

Abstract

A method for the synthesis of N-protected 3,6-aminoalkyl-2,5-diketopiperazines is provided. The method includes obtaining a cyclic α-N protected active amino ester and adding it to a mixture of an amine catalyst in an organic solvent.

IPC Classes  ?

• C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
• C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• C07D 241/10 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members

Abstract

The present invention relates to pharmaceutical compositions for inhalation comprising a therapeutically effective dose of clofazimine wherein the clofazimine is provided in the form of a suspension, and processes for their preparation. Furthermore, the present invention provides pharmaceutical combinations comprising clofazimine in the form of an aerosol for pulmonary inhalation. The combinations and compositions provided by the present invention may be used in the treatment and/or prophylaxis of pulmonary infections caused by mycobacteria and other gram-positive bacteria, and of pulmonary fungal infections.

IPC Classes  ?

• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 9/10 - DispersionsEmulsions
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 47/02 - Inorganic compounds
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Abstract

This application concerns pharmaceutical compositions comprising cannabinoids which are suitable for subcutaneous administration in human subjects. Thus, this application concerns pharmaceutical compositions for subcutaneous administration. The pharmaceutical compositions according to the invention are particularly suitable for subcutaneous administration, which is advantageous for improving bioavailability and reducing toxicity.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/05 - Phenols
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
• A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters

Abstract

The present disclosure relates to inhalable dry powder compositions comprising cannabinoids. In particular, the formulations are intended for use with dry powder inhalers for single use or multiple use comprising replaceable cartridges for delivery to the deep lung as medicinal agents. The inhalable dry powders are useful in the treatment of diseases and disorders, including pain.

IPC Classes  ?

• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/05 - Phenols
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets

Goods & Services

Providing a website for medical professionals and patients featuring medical information and data; providing medical information and data; providing medical information via posts on on-line social media platforms in the medical, pharmaceutical and health fields featuring information related to health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and/or drug compatibility in relation to therapy and treatment of individuals, adherence to pharmaceutical protocols, and the diagnostic prophylactic and therapeutic properties of pharmaceuticals; medical care consulting services in the fields of diagnostics, patient treatment and treatment protocols

Abstract

A method, composition and kit for the treatment of fibrotic lung disease are disclosed. The method utilizes a combination product for inhalation comprising a therapeutic amount of a dry powder formulation provided in an inhaler to be administered to a subject in need by oral inhalation. The composition comprise diketopiperazine particles for pulmonary inhalation.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A method, composition and kit for the treatment of fibrotic lung disease are disclosed. The method utilizes a combination product for inhalation comprising a therapeutic amount of a dry powder formulation provided in an inhaler to be administered to a subject in need by oral inhalation. The composition comprise diketopiperazine particles for pulmonary inhalation.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Methods of treatment of pulmonary hypertension comprising dry powder inhalation administration of imatinib, a pharmaceutically acceptable salt, or a derivative thereof, are provided. Dry powder inhalable compositions comprising imatinib, a pharmaceutically acceptable salt, or a derivative thereof, are also provided as well as methods of making the same.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/14 - Particulate form, e.g. powders
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

Methods of treatment of pulmonary hypertension comprising dry powder inhalation administration of imatinib, a pharmaceutically acceptable salt, or a derivative thereof, are provided. Dry powder inhalable compositions comprising imatinib, a pharmaceutically acceptable salt, or a derivative thereof, are also provided as well as methods of making the same.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/14 - Particulate form, e.g. powders
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

A medicament delivery device may comprise a medicament chamber configured to hold a medicament, a plunger configured to move relative to the medicament chamber to expel the medicament from the medicament chamber, a pin configured to move from a first pin position wherein the pin prevents movement of the plunger to a second pin position wherein the pin allows movement of the plunger, an actuation assembly configured to move the pin from the first pin position to the second pin position, and a needle coupled to the medicament chamber. The medicament may flow through the needle from the medicament chamber to a user. The actuation assembly may be configured to automatically move the pin after a predetermined time delay.

IPC Classes  ?

• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
• A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles

Goods & Services

Providing medical information via posts on on-line social media platforms in the medical, pharmaceutical and health fields featuring information related to health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and/or drug compatibility in relation to therapy and treatment of individuals, adherence to pharmaceutical protocols, and the diagnostic prophylactic and therapeutic properties of pharmaceuticals; medical care consulting services in the fields of diagnostics, patient treatment and treatment protocols

Abstract

Methods of treatment of pulmonary hypertension comprising dry powder inhalation administration of imatinib, a pharmaceutically acceptable salt, or a derivative thereof, are provided. Dry powder inhalable compositions comprising imatinib, a pharmaceutically acceptable salt, or a derivative thereof, are also provided as well as methods of making the same.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin, oxyntomodulin and glucagon-like peptide.

IPC Classes  ?

• A61M 15/00 - Inhalators
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/22 - Hormones
• A61K 38/26 - Glucagons
• A61K 38/28 - Insulins
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Goods & Services

Downloadable software in the nature of a mobile application for reading information and data from a medical device, for use by medical professionals and/or patients; downloadable software for coaching and teaching intended to assist users to properly use the inhaler, namely, training with inhalers without medication for medical instruction purposes to teach inhaler use technique

Goods & Services

Downloadable software in the nature of a mobile application for reading medical information and data from a medical device, for use by medical professionals and patients

Goods & Services

Downloadable software in the nature of a mobile application for reading medical information and data from a medical device, for use by medical professionals and patients Medical devices in the nature of inhalers, or inhaler accessory devices used to measure patient inhalation effort and to train patients in personal inhaler use; medical devices in the nature of inhalers, or inhaler accessory devices with features for measuring respiratory effort and facilitating the training of patients in use of inhalers; medical devices in the nature of inhalers, or inhaler accessory devices with features for the measurement of respiratory patterns of patients; medical devices included as a component of inhaler systems for medical use, namely, patient monitors for monitoring and measuring respiration; medical devices included as a component of inhaler systems for medical use, namely, devices used to indicate dosing of medication; medical devices included as a component of inhaler systems for medical use, namely, devices used to transmit and receive data regarding inhalation, respiration, or dosage

Goods & Services

Medical devices in the nature of inhalers, or inhaler accessory devices used to measure patient inhalation effort and to train patients in personal inhaler use; medical devices in the nature of inhalers, or inhaler accessory devices with features for measuring respiratory effort and facilitating the training of patients in use of inhalers; medical devices in the nature of inhalers, or inhaler accessory devices with features for the measurement of respiratory patterns of patients; medical devices included as a component of inhaler systems for medical use, namely, patient monitors for monitoring and measuring respiration; medical devices included as a component of inhaler systems for medical use, namely, devices used to indicate dosing of medication; medical devices included as a component of inhaler systems for medical use, namely, devices used to transmit and receive data regarding inhalation, respiration, or dosage

Abstract

Disclosed herein are DKP microcrystals made by an improved method where they do not irreversibly self-assemble into microparticles. The microcrystals can be dispersed by atomization and re-formed by spray drying into particles having spherical shell morphology. Active agents and excipients can be incorporated into the particles by spray drying a solution containing the components to be incorporated into microcrystalline diketopiperazine particles. In particular, the microcrystalline particle compositions are suitable for pulmonary drug delivery of one or more peptides, proteins, nucleic acids and/or small organic molecules.

IPC Classes  ?

• C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
• A61K 38/26 - Glucagons
• A61K 38/28 - Insulins
• A61K 9/14 - Particulate form, e.g. powders
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 9/50 - Microcapsules
• B01D 1/18 - Evaporating by spraying to obtain dry solids

Abstract

A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided.

IPC Classes  ?

• A61M 15/00 - Inhalators
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/22 - Hormones
• A61K 38/26 - Glucagons
• A61K 38/28 - Insulins

Abstract

The present invention relates to pharmaceutical compositions for inhalation comprising a therapeutically effective dose of bedaquiline wherein the bedaquiline is provided in the form of a suspension, or in which the bedaquiline is provided in the form of a dry powder, and processes for their preparation. Furthermore, the present invention provides pharmaceutical combinations comprising bedaquiline in the form of an aerosol for pulmonary inhalation. The combinations and compositions provided by the present invention may be used in the treatment and/or prophylaxis of pulmonary infections caused by mycobacteria and other gram-positive bacteria.

IPC Classes  ?

• A61K 31/47 - QuinolinesIsoquinolines
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61J 7/00 - Devices for administering medicines orally, e.g. spoonsPill counting devicesArrangements for time indication or reminder for taking medicine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61P 31/04 - Antibacterial agents

Abstract

A fluid delivery device for administering a first medicament and a second medicament includes a first fluid reservoir configured to contain the first medicament and a second fluid reservoir configured to contain the second medicament. The fluid delivery device may include one or more basal drive mechanisms to provide a basal delivery of one or more of the first and second medicaments. The fluid delivery device may further include one or more bolus drive mechanisms to provide a bolus delivery of one or more of the first and second medicaments.

IPC Classes  ?

• A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
• A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
• A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
• A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles

Goods & Services

Arranging and conducting conferences, seminars and non-downloadable webinars in the field of health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and drug compatibility in relation to therapy and treatment of individuals, adherence to pharmaceutical protocols, and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals; providing non-downloadable podcasts in the field of health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and/or drug compatibility in relation to therapy and treatment of individuals, adherence to pharmaceutical protocols, and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals (terms considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations). Provision of information related to health, wellness, healthcare, patient support services, pharmaceuticals, pharmaceutical access, drug safety and/or drug compatibility in relation to therapy and treatment of individuals, adherence to pharmaceutical protocols, and the diagnostic, prophylactic and therapeutic properties of pharmaceuticals.

Abstract

Provided are novel treprostinil based compounds, methods of treatment using the same, and their methods of making.

IPC Classes  ?

• C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 9/12 - Antihypertensives
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61P 11/06 - Antiasthmatics
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

Provided are novel treprostinil based compounds, methods of treatment using the same, and their methods of making.

IPC Classes  ?

• C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
• A61K 31/4965 - Non-condensed pyrazines
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 9/12 - Antihypertensives
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61P 11/06 - Antiasthmatics
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like